{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:44:44Z","timestamp":1788435884705,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T00:00:00Z","timestamp":1550188800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00210-019-01628-z","type":"journal-article","created":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T14:20:31Z","timestamp":1550240431000},"page":"723-728","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Analgesic effects of mirogabalin, a novel ligand for \u03b12\u03b4 subunit of voltage-gated calcium channels, in experimental animal models of fibromyalgia"],"prefix":"10.1007","volume":"392","author":[{"given":"Kensuke","family":"Saeki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-ichi","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Kano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Domon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohisa","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,15]]},"reference":[{"key":"1628_CR1","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.3899\/jrheum.170095","volume":"44","author":"JN Ablin","year":"2017","unstructured":"Ablin JN, Wolfe F (2017) A comparative evaluation of the 2011 and 2016 criteria for fibromyalgia. J Rheumatol 44:1271\u20131276. \n                    https:\/\/doi.org\/10.3899\/jrheum.170095","journal-title":"J Rheumatol"},{"key":"1628_CR2","doi-asserted-by":"publisher","first-page":"485272","DOI":"10.1155\/2013\/485272","volume":"2013","author":"J Ablin","year":"2013","unstructured":"Ablin J, Fitzcharles MA, Buskila D, Shir Y, Sommer C, H\u00e4user W (2013) Treatment of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines with special emphasis on complementary and alternative therapies. Evid Based Complement Alternat Med 2013:485272. \n                    https:\/\/doi.org\/10.1155\/2013\/485272","journal-title":"Evid Based Complement Alternat Med"},{"issue":"Suppl 1","key":"1628_CR3","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1007\/s40122-017-0087-0","volume":"6","author":"G Cruccu","year":"2017","unstructured":"Cruccu G, Truini A (2017) A review of neuropathic pain: from guidelines to clinical practice. Pain Ther 6(Suppl 1):S35\u2013S42. \n                    https:\/\/doi.org\/10.1007\/s40122-017-0087-0","journal-title":"Pain Ther"},{"key":"1628_CR4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/ar4402","volume":"15","author":"JM DeSantana","year":"2013","unstructured":"DeSantana JM, da Cruz KM, Sluka KA (2013) Animal models of fibromyalgia. Arthritis Res Ther 15:222. \n                    https:\/\/doi.org\/10.1186\/ar4402","journal-title":"Arthritis Res Ther"},{"key":"1628_CR5","unstructured":"Domon Y, Arakawa N, Yasuda S, Saeki K, Kano M, Kato M, Kitano Y (2015) Analgesic effects of the novel alpha-2-delta ligand mirogabalin (DS-5565) in experimental animal models of fibromyalgia. Arthritis Rheum 67(suppl 10)"},{"key":"1628_CR6","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1124\/jpet.117.247551","volume":"365","author":"Y Domon","year":"2018","unstructured":"Domon Y, Arakawa N, Inoue T, Matsuda F, Takahashi M, Yamamura N, Kai K, Kitano Y (2018a) Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the \u03b12\u03b4 subunit of voltage-gated calcium channels. J Pharmacol Exp Ther 365:573\u2013582. \n                    https:\/\/doi.org\/10.1124\/jpet.117.247551","journal-title":"J Pharmacol Exp Ther"},{"key":"1628_CR7","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1691\/ph.2018.8550","volume":"73","author":"Y Domon","year":"2018","unstructured":"Domon Y, Kitano Y, Makino M (2018b) Analgesic effects of the novel \u03b12\u03b4 ligand mirogabalin in a rat model of spinal cord injury. Pharmazie 73:659\u2013661. \n                    https:\/\/doi.org\/10.1691\/ph.2018.8550","journal-title":"Pharmazie"},{"key":"1628_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.tips.2006.12.006","volume":"28","author":"DJ Dooley","year":"2007","unstructured":"Dooley DJ, Taylor CP, Donevan S, Feltner D (2007) Ca2+ channel \u03b12\u03b4 ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 28:75\u201382. \n                    https:\/\/doi.org\/10.1016\/j.tips.2006.12.006","journal-title":"Trends Pharmacol Sci"},{"key":"1628_CR9","doi-asserted-by":"publisher","first-page":"17537","DOI":"10.1073\/pnas.0409066103","volume":"103","author":"MJ Field","year":"2006","unstructured":"Field MJ, Cox PJ, Stott E, Melrose H, Offord J, Su TZ, Bramwell S, Corradini L, England S, Winks J, Kinloch RA, Hendrich J, Dolphin AC, Webb T, Williams D (2006) Identification of the \u03b12\u03b4-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci U S A 103:17537\u201317542. \n                    https:\/\/doi.org\/10.1073\/pnas.0409066103","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1628_CR10","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1002\/ejp.1252","volume":"22","author":"MA Fitzcharles","year":"2018","unstructured":"Fitzcharles MA, Perrot S, H\u00e4user W (2018) Comorbid fibromyalgia: a qualitative review of prevalence and importance. Eur J Pain 22:1565\u20131576. \n                    https:\/\/doi.org\/10.1002\/ejp.1252","journal-title":"Eur J Pain"},{"key":"1628_CR11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/jcph.567","volume":"56","author":"MM Hutmacher","year":"2016","unstructured":"Hutmacher MM, Frame B, Miller R, Truitt K, Merante D (2016) Exposure-response modeling of average daily pain score, and dizziness and somnolence, for mirogabalin (DS-5565) in patients with diabetic peripheral neuropathic pain. J Clin Pharmacol 56:67\u201377. \n                    https:\/\/doi.org\/10.1002\/jcph.567","journal-title":"J Clin Pharmacol"},{"key":"1628_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.pain.2006.04.022","volume":"125","author":"CY Li","year":"2006","unstructured":"Li CY, Zhang XL, Matthews EA, Li KW, Kurwa A, Boroujerdi A, Gross J, Gold MS, Dickenson AH, Feng G, Luo ZD (2006) Calcium channel \u03b12\u03b4-1 subunit mediates spinal hyperexcitability in pain modulation. Pain 125:20\u201334. \n                    https:\/\/doi.org\/10.1016\/j.pain.2006.04.022","journal-title":"Pain"},{"key":"1628_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ejphar.2011.05.054","volume":"667","author":"Z Li","year":"2011","unstructured":"Li Z, Taylor CP, Weber M, Piechan J, Prior F, Bian F, Cui M, Hoffman D, Donevan S (2011) Pregabalin is a potent and selective ligand for \u03b12\u03b4-1 and \u03b12\u03b4-2 calcium channel subunits. Eur J Pharmacol 667:80\u201390. \n                    https:\/\/doi.org\/10.1016\/j.ejphar.2011.05.054","journal-title":"Eur J Pharmacol"},{"key":"1628_CR14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.physbeh.2014.03.030","volume":"131","author":"YT Liu","year":"2014","unstructured":"Liu YT, Shao YW, Yen CT, Shaw FZ (2014) Acid-induced hyperalgesia and anxio-depressive comorbidity in rats. Physiol Behav 131:105\u2013105. \n                    https:\/\/doi.org\/10.1016\/j.physbeh.2014.03.030","journal-title":"Physiol Behav"},{"key":"1628_CR15","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1136\/annrheumdis-2016-209724","volume":"76","author":"GJ Macfarlane","year":"2017","unstructured":"Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, H\u00e4user W, Flu\u00df E, Choy E, Kosek E, Amris K, Branco J, Dincer F, Leino-Arjas P, Longley K, McCarthy GM, Makri S, Perrot S, Sarzi-Puttini P, Taylor A, Jones GT (2017) EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis 76:318\u2013328. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2016-209724","journal-title":"Ann Rheum Dis"},{"key":"1628_CR16","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1093\/pm\/pnw342","volume":"18","author":"D Merante","year":"2017","unstructured":"Merante D, Rosenstock J, Sharma U, Feins K, Hsu C, Vinik A (2017) Efficacy of mirogabalin (DS-5565) on patient-reported pain and sleep interference in patients with diabetic neuropathic pain: secondary outcomes of a phase II proof-of-concept study. Pain Med 18:2198\u20132207. \n                    https:\/\/doi.org\/10.1093\/pm\/pnw342","journal-title":"Pain Med"},{"key":"1628_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jphs.2016.01.002","volume":"131","author":"T Mukae","year":"2016","unstructured":"Mukae T, Fujita W, Ueda H (2016) P-glycoprotein inhibitors improve effective dose and time of pregabalin to inhibit intermittent cold stress-induced central pain. J Pharmacol Sci 131:64\u201367. \n                    https:\/\/doi.org\/10.1016\/j.jphs.2016.01.002","journal-title":"J Pharmacol Sci"},{"key":"1628_CR18","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1517\/17460441.2015.1066776","volume":"10","author":"Y Nagakura","year":"2015","unstructured":"Nagakura Y (2015) Challenges in drug discovery for overcoming \u2018dysfunctional pain\u2019: an emerging category of chronic pain. Expert Opin Drug Discovery 10:1043\u20131045. \n                    https:\/\/doi.org\/10.1517\/17460441.2015.1066776","journal-title":"Expert Opin Drug Discovery"},{"key":"1628_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.pain.2009.05.024","volume":"146","author":"Y Nagakura","year":"2009","unstructured":"Nagakura Y, Oe T, Aoki T, Matsuoka N (2009) Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: a putative animal model of fibromyalgia. Pain 146:26\u201333. \n                    https:\/\/doi.org\/10.1016\/j.pain.2009.05.024","journal-title":"Pain"},{"key":"1628_CR20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1744-8069-4-52","volume":"4","author":"M Nishiyori","year":"2008","unstructured":"Nishiyori M, Ueda H (2008) Prolonged gabapentin analgesia in an experimental mouse model of fibromyalgia. Mol Pain 4:52. \n                    https:\/\/doi.org\/10.1186\/1744-8069-4-52","journal-title":"Mol Pain"},{"key":"1628_CR21","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.neulet.2010.01.080","volume":"472","author":"M Nishiyori","year":"2010","unstructured":"Nishiyori M, Nagai J, Nakazawa T, Ueda H (2010) Absence of morphine analgesia and its underlying descending serotonergic activation in an experimental mouse model of fibromyalgia. Neurosci Lett 472:184\u2013187. \n                    https:\/\/doi.org\/10.1016\/j.neulet.2010.01.080","journal-title":"Neurosci Lett"},{"issue":"10 Suppl","key":"1628_CR22","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.amjmed.2009.04.007","volume":"122","author":"AB O\u2019Connor","year":"2009","unstructured":"O\u2019Connor AB, Dworkin RH (2009) Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 122(10 Suppl):S22\u2013S32. \n                    https:\/\/doi.org\/10.1016\/j.amjmed.2009.04.007","journal-title":"Am J Med"},{"key":"1628_CR23","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1254\/jphs.08319FP","volume":"109","author":"Y Omori","year":"2009","unstructured":"Omori Y, Kagaya K, Enomoto R, Sasaki A, Andoh T, Nojima H, Takahata H, Kuraishi Y (2009) A mouse model of sural nerve injury-induced neuropathy: gabapentin inhibits pain-related behaviors and the hyperactivity of wide-dynamic range neurons in the dorsal horn. J Pharmacol Sci 109:532\u2013539. \n                    https:\/\/doi.org\/10.1254\/jphs.08319FP","journal-title":"J Pharmacol Sci"},{"key":"1628_CR24","doi-asserted-by":"publisher","first-page":"16412","DOI":"10.1523\/JNEUROSCI.1026-13.2013","volume":"33","author":"R Patel","year":"2013","unstructured":"Patel R, Bauer CS, Nieto-Rostro M, Margas W, Ferron L, Chaggar K, Crews K, Ramirez JD, Bennett DL, Schwartz A, Dickenson AH, Dolphin AC (2013) \u03b12\u03b4-1 gene deletion affects somatosensory neuron function and delays mechanical hypersensitivity in response to peripheral nerve damage. J Neurosci 33:16412\u201316426. \n                    https:\/\/doi.org\/10.1523\/JNEUROSCI.1026-13.2013","journal-title":"J Neurosci"},{"key":"1628_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/1097-4598(200101)24:1<37::AID-MUS4>3.0.CO;2-8","volume":"24","author":"KA Sluka","year":"2001","unstructured":"Sluka KA, Kalra A, Moore SA (2001) Unilateral intramuscular injections of acidic saline produce a bilateral, long-lasting hyperalgesia. Muscle Nerve 24:37\u201346. \n                    https:\/\/doi.org\/10.1002\/1097-4598(200101)24:1<37::AID-MUS4>3.0.CO;2-8","journal-title":"Muscle Nerve"},{"key":"1628_CR26","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.tips.2013.04.001","volume":"34","author":"SM Stahl","year":"2013","unstructured":"Stahl SM, Porreca F, Taylor CP, Cheung R, Thorpe AJ, Clair A (2013) The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacological activities? Trends Pharmacol Sci 34:332\u2013339. \n                    https:\/\/doi.org\/10.1016\/j.tips.2013.04.001","journal-title":"Trends Pharmacol Sci"},{"key":"1628_CR27","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.2337\/dc14-1044","volume":"37","author":"A Vinik","year":"2014","unstructured":"Vinik A, Rosenstock J, Sharma U, Feins K, Hsu C, Merante D (2014) DS5565-A-U201 US Phase II Study Investigators. Efficacy and safety of mirogabalin besylate (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes Care 37:3253\u20133261. \n                    https:\/\/doi.org\/10.2337\/dc14-1044","journal-title":"Diabetes Care"},{"key":"1628_CR28","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jpain.2006.11.007","volume":"8","author":"T Yokoyama","year":"2007","unstructured":"Yokoyama T, Maeda Y, Audette KM, Sluka KA (2007) Pregabalin reduces muscle and cutaneous hyperalgesia in two models of chronic muscle pain in rats. J Pain 8:422\u2013429. \n                    https:\/\/doi.org\/10.1016\/j.jpain.2006.11.007","journal-title":"J Pain"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00210-019-01628-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-019-01628-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-019-01628-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T19:14:25Z","timestamp":1581707665000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00210-019-01628-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,15]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["1628"],"URL":"https:\/\/doi.org\/10.1007\/s00210-019-01628-z","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,15]]},"assertion":[{"value":"25 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were conducted in accordance with the Guidelines for Management and Welfare of Experimental Animals (Hashima Laboratory, Nihon Bioresearch Inc., April 2, 2007; modified on August 27, 2010) and the Guideline of the Institutional Animal Care and Use Committee of Daiichi Sankyo Co., Ltd. This article does not contain any studies with human participants performed by any of the authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KS, SY, MKato, and MKano are employees of Nihon Bioresearch Inc., while YD, NA, and YK are employees of Daiichi Sankyo Co., Ltd. This study was sponsored by Daiichi Sankyo Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}